Login Register Cart 0
Generic placeholder image

Current Psychiatry Research and Reviews

Editor-in-Chief

ISSN (Print): 2666-0822
ISSN (Online): 2666-0830

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

The Secure Therapeutic Effects of Recently Developed Antipsychotic Drugs and Updated Neural Networks in Schizophrenia

In Press, (this is not the final "Version of Record"). Available online 03 April, 2024
Author(s): Felix-Martin Werner* and Rafael Coveñas
Published on: 03 April, 2024

DOI: 10.2174/0126660822287649240326043815

Price: $95

Abstract

Introduction: Schizophrenia and schizoaffective disorder are treated in most cases with antipsychotic drugs of the second generation. These drugs block dopaminergic and serotonergic receptors, i.e., D2 and 5-HT2A receptors, and cause different adverse effects, for example, movement disturbances of the extrapyramidal system and adverse effects of vital parameters and of the heart. These drugs treat positive symptoms in schizophrenia and, to a lesser extent, negative symptoms. This review presents the development of newer antipsychotic drugs.

Methods/Material: References were taken from PubMed after using the following keywords: schizophrenia, schizoaffective disorder, antipsychotic drug, neurotransmitter and neuropeptide. Among these newer antipsychotic drugs are cariprazine, brexipiprazole and lumateperone, which exert a partial agonistic effect at D2 and 5-HT2A receptors, pimavanserin, a 5-HT2A receptor antagonist which treats negative symptoms in schizophrenia as add-on therapy, olanzapine combined with samidorphan, which reduces weight gain, and M4 or M1 receptor agonists, for example, xanomeline with an antipsychotic effect combined with trospium, an anticholinergic drug. Neural networks were updated in order to deduce the antipsychotic mechanism of action of newer antipsychotic drugs, especially xanomeline.

Results: The newer antipsychotic drugs cariprazine, brexipiprazole and lumateperone show antipsychotic, antimanic and anti-depressive effects, however, the efficacy on psychotic symptoms in long-term treatment has not yet been examined. Pimavanserin reduces negative symptoms in schizophrenia as an additional pharmacotherapy to treat this disorder. Olanzapine combined with samidorphan exerts good antipsychotic effects and reduces weight gain. The new antipsychotic drug xanomeline, the antipsychotic effect of which is quite different from the antidopaminergic effect, treats positive and negative symptoms in schizophrenia. Its mechanism of action was deduced from the neural networks presented. The long-term efficacy should still be examined.

Conclusion: This review is focused on newer antipsychotic drugs. The long-term efficacy of cariprazine, brexipiprazole and lumateperone in the treatment of schizophrenia should be examined further. Neural networks in the brain areas involved in schizophrenia should be examined and updated furthermore. Newer antipsychotic drugs ,for example, xanomeline, an M4 or M1 receptor agonist, which has been combined with trospium, an anticholinergic drug, the mechanism of action of which can be derived from the neural network suggested in this review.

[1]
Werner FM, Coveñas R. Classical neurotransmitters and neuropeptides involved in schizoaffective disorder: Focus on prophylactic medication. Sharjah: Bentham Science Publishers 2016.
[http://dx.doi.org/10.2174/97816810821581160101]
[2]
Werner FM, Coveñas R. Safety of antipsychotic drugs: Focus on therapeutic and adverse effects. Expert Opin Drug Saf 2014; 13(8): 1031-42.
[http://dx.doi.org/10.1517/14740338.2014.935761] [PMID: 24975932]
[3]
Werner FM, Coveñas R. Risk genes in schizophrenia and their importance in choosing the appropriate antipsychotic treatment. Curr Pharm Des 2021; 27(30): 3281-92.
[http://dx.doi.org/10.2174/1381612827666210215151333] [PMID: 33588721]
[4]
Revuelta GM, Terán PJM, Ruiz JM, et al. Antipsychotic treatment effectiveness in first episode of psychosis: PAFIP 3-year follow-up randomized clinical trials comparing haloperidol, olanzapine, risperidone, aripiprazole, quetiapine, and ziprasidone. Int J Neuropsychopharmacol 2020; 23(4): 217-29.
[http://dx.doi.org/10.1093/ijnp/pyaa004] [PMID: 31974576]
[5]
Paik J. Olanzapine/Samidorphan: First approval. Drugs 2021; 81(12): 1431-6.
[http://dx.doi.org/10.1007/s40265-021-01568-0] [PMID: 34304374]
[6]
Pahwa M, Sleem A, Elsayed OH, Good ME, El-Mallakh RS. New antipsychotic medications in the last decade. Curr Psychiatry Rep 2021; 23(12): 87.
[http://dx.doi.org/10.1007/s11920-021-01298-w] [PMID: 34843030]
[7]
Caccia S, Invernizzi RW, Nobili A, Pasina L. A new generation of antipsychotics: Pharmacology and clinical utility of cariprazine in schizophrenia. Ther Clin Risk Manag 2013; 9: 319-28.
[http://dx.doi.org/10.2147/TCRM.S35137] [PMID: 23966785]
[8]
Werner FM, Coveñas R. New developments in the management of schizophrenia and bipolar disorder: Potential use of cariprazine. Ther Clin Risk Manag 2015; 11: 1657-61.
[PMID: 26586950]
[9]
Laszlovszky I, Barabássy Á, Németh G. Cariprazine, a broad-spectrum antipsychotic for the treatment of schizophrenia: Pharmacology, efficacy and safety. Adv Ther 2021; 38(7): 3652-73.
[http://dx.doi.org/10.1007/s12325-021-01797-5] [PMID: 34091867]
[10]
Orzelska-Górka J, Mikulska J, Wiszniewska A, Biała G. New atypical antipsychotics in the treatment of schizophrenia and depression. Int J Mol Sci 2022; 23(18): 10624.
[http://dx.doi.org/10.3390/ijms231810624] [PMID: 36142523]
[11]
Mohr P, Masopust J, Kopeček M. Dopamine receptor partial agonists: Do they differ in their clinical efficacy? Front Psychiatry 2022; 12: 781946.
[http://dx.doi.org/10.3389/fpsyt.2021.781946] [PMID: 35145438]
[12]
Wu H, Siafis S, Hamza T, et al. Antipsychotic-induced weight gain: Dose-response meta-analysis of randomized controlled trials. Schizophr Bull 2022; 48(3): 643-54.
[http://dx.doi.org/10.1093/schbul/sbac001] [PMID: 35137229]
[13]
de Bartolomeis A, Ciccarelli M, Vellucci L, Fornaro M, Iasevoli F, Barone A. Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia. Expert Opin Pharmacother 2022; 23(18): 2035-52.
[http://dx.doi.org/10.1080/14656566.2022.2145884] [PMID: 36368055]
[14]
Thoma SJ, Chalkou K, Dörries C, et al. Comparative efficacy and tolerability of 32 oral and injectable long-acting antipsychotics for the maintenance treatment of adults with schizophrenia: A systematic review and network meta-analysis. Lancet 2022; 399: 824-36.
[http://dx.doi.org/10.1016/S0140-6736(21)01997-8] [PMID: 35219395]
[15]
Grossberg GT, Kohegyi E, Mergel V, et al. Efficacy and safety of brexipiprazole for the treatment of agitation in Alzheimer’s dementia: Two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry 2020; 28(4): 383-400.
[http://dx.doi.org/10.1016/j.jagp.2019.09.009] [PMID: 31708380]
[16]
Ishigooka J, Iwashita S, Higashi K, Liew EL, Tadori Y. Pharmacokinetics and safety of brexipiprazole following multiple-dose administration to Japanese patients with schizophrenia. J Clin Pharmacol 2018; 58(1): 74-80.
[http://dx.doi.org/10.1002/jcph.979] [PMID: 28750151]
[17]
Greig SL. Brexipiprazole: First global approval. Drugs 2015; 75(14): 1687-97.
[http://dx.doi.org/10.1007/s40265-015-0462-2] [PMID: 26310190]
[18]
Edinoff A, Wu N, deBoisblanc C, et al. Lumateperone for the treatment of schizophrenia. Psychopharmacol Bull 2020; 50(4): 32-59.
[PMID: 33012872]
[19]
Werner FM, Coveñas R. The novel antipsychotic drug cariprazine and cognition enhancing drugs: Indications for their use as the add-on therapy in schizophrenia. Curr Pharm Des 2021; 27(39): 4033-8.
[http://dx.doi.org/10.2174/1381612826666201210123229] [PMID: 33302854]
[20]
Blair HA. Lumateperone: First approval. Drugs 2020; 80(4): 417-23.
[http://dx.doi.org/10.1007/s40265-020-01271-6] [PMID: 32060882]
[21]
Snyder GL, Vanover KE, Davis RE, Li P, Fienberg A, Mates S. A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia.In: Advances in Pharmacology Zorn SH. Elsevier 2021; pp. 253-76.
[http://dx.doi.org/10.1016/bs.apha.2020.09.001]
[22]
Kirola BD, Arango C, Fava M, et al. Pimavanserin for negative symptoms of schizophrenia: Results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry 2022; 9(1): 46-58.
[http://dx.doi.org/10.1016/S2215-0366(21)00386-2] [PMID: 34861170]
[23]
Tsapakis EM, Diakaki K, Miliaras A, Fountoulakis KN. Novel compounds in the treatment of schizophrenia – A systematic review. Brain Sci 2023; 13(8): 1193.
[http://dx.doi.org/10.3390/brainsci13081193] [PMID: 37626549]
[24]
Vieta E, Montes JM. A review of asenapine in the treatment of bipolar disorder. Clin Drug Investig 2018; 38(2): 87-99.
[http://dx.doi.org/10.1007/s40261-017-0592-2] [PMID: 29067671]
[25]
Carrithers B, Mallakh ERS. Transdermal asenapine in schizophrenia: A systematic review. Patient Prefer Adherence 2020; 14: 1541-51.
[http://dx.doi.org/10.2147/PPA.S235104] [PMID: 32943849]
[26]
Citrome L, Walling DP, Zeni CM, et al. Efficacy and safety of HP-3070, an asenapine transdermal system, in patients with schizophrenia: A phase 3, randomized, placebo-controlled study. J Clin Psychiatry 2020; 82: 20m13602.
[27]
Minassian A, Young JW. Evaluation of the clinical efficacy of asenapine in schizophrenia. Expert Opin Pharmacother 2010; 11(12): 2107-15.
[http://dx.doi.org/10.1517/14656566.2010.506188] [PMID: 20642375]
[28]
Chakrabarti A, Bagnall A, Chue P, et al. Loxapine for schizophrenia. Cochrane Database Syst Rev 2007; 2007: CD001943.23.
[http://dx.doi.org/10.1002/14651858.CD001943.pub2]
[29]
Faden J, Citrome L. Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Neuropsychiatr Dis Treat 2019; 15: 2273-83.
[http://dx.doi.org/10.2147/NDT.S173567] [PMID: 31496709]
[30]
Dodd S, F Carvalho A, Puri BK, et al. Trace amine-associated receptor 1 (TAAR1): A new drug target for psychiatry? Neurosci Biobehav Rev 2021; 120: 537-41.
[http://dx.doi.org/10.1016/j.neubiorev.2020.09.028] [PMID: 33031817]
[31]
Dean B, Scarr E. Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia. Psychiatry Res 2020; 288: 112989.
[http://dx.doi.org/10.1016/j.psychres.2020.112989] [PMID: 32315882]
[32]
Dean B. Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal. Expert Opin Investig Drugs 2023; 32(12): 1113-21.
[33]
Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet 2024; 403(10422): 160-70.
[PMID: 38104575]
[34]
Jones CK, Byun N, Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 2012; 37(1): 16-42.
[http://dx.doi.org/10.1038/npp.2011.199] [PMID: 21956443]
[35]
Yang A, Tsai SJ. New targets for schizophrenia treatment beyond the dopamine hypothesis. Int J Mol Sci 2017; 18(8): 1689.
[http://dx.doi.org/10.3390/ijms18081689] [PMID: 28771182]
[36]
Seeman P. Schizophrenia and dopamine receptors. Eur Neuropsychopharmacol 2013; 23(9): 999-1009.
[http://dx.doi.org/10.1016/j.euroneuro.2013.06.005] [PMID: 23860356]
[37]
Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectr 2018; 23(3): 187-91.
[http://dx.doi.org/10.1017/S1092852918001013] [PMID: 29954475]
[38]
Kim SA. 5-HT1A and 5-HT2A signaling, desensitization, and downregulation: Serotonergic dysfunction and abnormal receptor density in schizophrenia and the prodrome. Cureus 2021; 13(6): e15811.
[http://dx.doi.org/10.7759/cureus.15811] [PMID: 34306878]
[39]
González-Burgos G, Lewis DA. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull 2008; 34(5): 944-61.
[http://dx.doi.org/10.1093/schbul/sbn070] [PMID: 18586694]
[40]
Shinkai T, De Luca V, Hwang R, et al. Association analyses of the DAOA/G30 and d-amino-acid oxidase genes in schizophrenia: Further evidence for a role in schizophrenia. Neuromolecular Med 2007; 9(2): 169-77.
[http://dx.doi.org/10.1007/BF02685890] [PMID: 17627036]
[41]
Ballaz SJ, Bourin M. Cholecystokinin-mediated modulation of anxiety and schizophrenia: A “Dimmer-Switch” hypothesis. Curr Neuropharmacol 2021; 19(7): 925-38.
[http://dx.doi.org/10.2174/1570159X18666201113145143] [PMID: 33185164]
[42]
Alherz F, Alherz M, Almusawi H. NMDAR hypofunction and somatostatin-expressing GABAergic interneurons and receptors: A newly identified correlation and its effects in schizophrenia. Schizophr Res Cogn 2017; 8: 1-6.
[http://dx.doi.org/10.1016/j.scog.2017.02.001] [PMID: 28740825]
[43]
Lanillos P, Oliva D, Philippsen A, Yamashita Y, Nagai Y, Cheng G. A review on neural network models of schizophrenia and autism spectrum disorder. Neural Netw 2020; 122: 338-63.
[http://dx.doi.org/10.1016/j.neunet.2019.10.014] [PMID: 31760370]
[44]
Mauri MC, Paletta S, Pace DC, et al. Clinical pharmacokinetics of atypical antipsychotics: An update. Clin Pharmacokinet 2019; 58(9): 1219-20.
[http://dx.doi.org/10.1007/s40262-019-00797-7] [PMID: 31214940]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy